Trifluoperazine exerts anti-osteosarcoma effect by inducing mitochondria-dependent apoptosis via AKT/TXNIP signaling pathway

The survival rates for patients with osteosarcoma (OS) have stagnated over the past few decades. It is essential to find new therapies and drugs. A licensed antipsychotic medication called trifluoperazine (TFP) significantly reduces the growth of several cancers. However, the exact molecular pathways of TFP in OS remain to be discovered. Our research revealed that TFP greatly reduced OS cell migration and growth and caused the arrest of G0/G1 cell cycle. Combined with RNA-Seq data and further research, we confirmed that TFP promoted Reactive Oxygen Species (ROS) production by elevating thioredoxin binding protein (TXNIP) expression to induce mitochondria-dependent Apoptosis. Interestingly, we first demonstrated that Akt was an upstream regulatory target of TXNIP in OS cells. Dephosphorylation of Akt led to an increase in TXNIP expression, further elucidating the Anticancer mechanism of TFP. In vivo, TFP inhibited subcutaneous OS cell proliferation and induced OS cell Apoptosis without noticeable side effects. In conclusion, our findings imply that TFP is a potential treatment for OS.

AKT/TXNIP; Mitochondria-Dependent Apoptosis; Osteosarcoma; Trifluoperazine.